Rhumbline Advisers cut its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 2.6% during the 4th quarter, HoldingsChannel reports. The firm owned 191,893 shares of the company’s stock after selling 5,049 shares during the quarter. Rhumbline Advisers’ holdings in Ionis Pharmaceuticals were worth $6,709,000 as of its most recent filing with the Securities & Exchange Commission.
Several other large investors also recently made changes to their positions in the company. Geode Capital Management LLC increased its stake in Ionis Pharmaceuticals by 7.4% during the 3rd quarter. Geode Capital Management LLC now owns 2,668,358 shares of the company’s stock valued at $106,922,000 after buying an additional 183,814 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in shares of Ionis Pharmaceuticals by 8.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,443,020 shares of the company’s stock valued at $57,807,000 after acquiring an additional 114,914 shares in the last quarter. ARK Investment Management LLC boosted its holdings in shares of Ionis Pharmaceuticals by 1.7% in the third quarter. ARK Investment Management LLC now owns 1,384,269 shares of the company’s stock valued at $55,454,000 after acquiring an additional 23,244 shares in the last quarter. Two Sigma Advisers LP increased its stake in shares of Ionis Pharmaceuticals by 3.5% during the third quarter. Two Sigma Advisers LP now owns 1,332,411 shares of the company’s stock valued at $53,376,000 after acquiring an additional 45,300 shares during the period. Finally, Groupama Asset Managment raised its holdings in Ionis Pharmaceuticals by 4.1% during the third quarter. Groupama Asset Managment now owns 916,060 shares of the company’s stock worth $367,000 after purchasing an additional 36,084 shares in the last quarter. Institutional investors and hedge funds own 93.86% of the company’s stock.
Insider Transactions at Ionis Pharmaceuticals
In related news, Director Michael R. Hayden acquired 5,000 shares of the company’s stock in a transaction that occurred on Monday, December 23rd. The shares were acquired at an average cost of $36.22 per share, for a total transaction of $181,100.00. Following the completion of the acquisition, the director now directly owns 35,219 shares in the company, valued at approximately $1,275,632.18. The trade was a 16.55 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Brett P. Monia sold 38,843 shares of the company’s stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $31.65, for a total value of $1,229,380.95. Following the transaction, the chief executive officer now directly owns 180,683 shares of the company’s stock, valued at $5,718,616.95. This represents a 17.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 111,816 shares of company stock valued at $3,603,914 over the last three months. 2.71% of the stock is currently owned by corporate insiders.
Wall Street Analysts Forecast Growth
Read Our Latest Research Report on Ionis Pharmaceuticals
Ionis Pharmaceuticals Stock Performance
NASDAQ IONS opened at $31.76 on Thursday. The company’s fifty day moving average is $33.32 and its two-hundred day moving average is $37.98. The firm has a market capitalization of $5.05 billion, a price-to-earnings ratio of -10.45 and a beta of 0.34. The company has a debt-to-equity ratio of 2.12, a current ratio of 8.47 and a quick ratio of 8.82. Ionis Pharmaceuticals, Inc. has a 52-week low of $30.23 and a 52-week high of $52.34.
Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) last posted its earnings results on Wednesday, February 19th. The company reported ($0.66) earnings per share for the quarter, topping the consensus estimate of ($1.12) by $0.46. Ionis Pharmaceuticals had a negative net margin of 64.25% and a negative return on equity of 100.05%. The business had revenue of $227.00 million for the quarter, compared to analyst estimates of $140.97 million. During the same quarter in the prior year, the firm earned $0.12 EPS. The firm’s quarterly revenue was down 30.2% compared to the same quarter last year. Equities research analysts forecast that Ionis Pharmaceuticals, Inc. will post -3.5 EPS for the current year.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.
Featured Articles
- Five stocks we like better than Ionis Pharmaceuticals
- Trading Stocks: RSI and Why it’s Useful
- Buffett’s on the Sidelines – Should You Follow?
- Stock Dividend Cuts Happen Are You Ready?
- AST SpaceMobile Stock Surges 17% After Analyst Upgrade
- What Investors Need to Know About Upcoming IPOs
- 3 Stocks With Triple-Digit PEs That Are Still Worth a Look
Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report).
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.